Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
Epistemonikos ID: 958f34ca3a577754bea1ef46ed01bc0c5e211dac
First added on: May 05, 2024